Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan

Pharmazie

Volumn 62, Issue 7, 2007, Pages 534-538

  Yang, Xiaochun ^a   Zhang, Chong ^a   Ying, Meidan ^a   Yang, Bo ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; TOPOTECAN; VASCULOTROPIN;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN PC3; CHORIOALLANTOIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; IC 50; INHIBITION KINETICS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACRIDINE ORANGE; ALLANTOIS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; ENDOTHELIAL CELLS; ETHIDIUM; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; TOPOTECAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447503912     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.7.6759     Document Type: Article

References (24)

1. Akbas SH, Timur M, Ozben T (2004) The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. J Surg Res 125: 49-55.
2. Biros E, Kohut A, Biros I, Kalina I, Bogyiova E, Stubna J (2002) A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. Lung Cancer 35: 231-235.
3. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR (2004) Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 39: 773-784.
4. Clements MK, Jones CB, Cumming M, Daoud SS (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44: 411-416.
5. Cordova-Alarcon E, Centeno F, Reyes-Esparza J, Garcia-Carranca A, Garrido E (2005) Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch Medl Res 36: 311-316.
6. Detmar M (2000) The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 1: S78-84.
7. Fayette J, Soria JC, Armand JP (2005) Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 41: 1109-1116.
8. Giordano FJ, Johnson RS (2001) Angiogenesis: the role of the microenvironment in flipping the switch. Cur Opin Genet Dev 11: 35-40.
9. Harris AL (2003) Angiogenesis as a new target for cancer control. Eur J Cancer 1: 1-2.
10. Haspel HC (2002) Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Microvasc Res 63: 304-315.
11. Hickman ES, Moroni MC, Helin K (2002) The role of p53 and pRB in apoptosis and cancer. Cur Opin Genet Dev 12: 60-66.
12. Jones MK, Sarfeh IJ, Tarnwaski AS (1998) Induction of in vitro angiogenesis in the endothelial-derived cell line, EA.hy926, by ethanol is mediated through PKC and MAPK. Biochem Bioph Res Co 249: 118-123.
13. Kondo T, Ohta T, Igura K, Hara Y, Kaji K (2002) Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett 180: 139-144.
14. Koutrafouri V, Lenodiadis L, Ferderigos N, Avgoustakis K, Livaniou E, Evangelatos GP, Ithakissios DS (2003) Synthesis and angiogenetic activity in the chick chorioallantoic membrane model of thymosin beta-15. Peptides 24: 107-115.
15. McCradden KW, Yokoi A, Thosani A, Softer SZ, Kim ES, Huang J, Manley C, O'toole K, Yamashiro DJ, Kandel JJ, Middlesworth W (2002) Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37: 857-861.
16. Miyagishi D, Ohno-Matsui K, Amagasa T, Morita I (2003) Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines. Cancer Lett 196: 77-85.
17. Moody TW, Chiles J, Moody E, Sieczkiewicz GJ, Kohn EC (2003) CAI inhibits the growth of small cell lung cancer cells. Lung Cancer 39: 279-288.
18. Ohneseit PA, Prager D, Kehlbach R, Rodemann HP (2005) Cell cycle effects of topotecan alone and in combination with irradiation. Radiother Oncol 75: 237-245.
19. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(5)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5: 181-187.
20. Sridhar SS, Shepherd FA (2003) Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42 Suppl 1: S81-91.
21. Stuart GC (2003) First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 90(3 Pt 2): S8-15.
22. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807.
23. 2 in vitro. Pharm Res 52: 174-182.
24. Woessmann W, Mivechi NF (2001) Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp Cell Res 264: 193-200.